Development of Pan-Anti-SARS-CoV-2 Agents through Allosteric Inhibition of nsp14/nsp10 Complex
SARS-CoV-2 nsp14 functions both as an exoribonuclease (ExoN) together with its critical cofactor nsp10 and as an S-adenosyl methionine-dependent (guanine-N7) methyltransferase (MTase), which makes it an attractive target for the development of pan-anti-SARS-CoV-2 drugs. Herein, we screened a panel of compounds (and drugs) and found that certain compounds, especially Bi(III)-based compounds, could allosterically inhibit both MTase and ExoN activities of nsp14 potently. We further demonstrated that Bi(III) binds to both nsp14 and nsp10, resulting in the release of Zn(II) ions from the enzymes as well as alternation of protein quaternary structures. The in vitro activities of the compounds were also validated in SARS-CoV-2-infected mammalian cells. Importantly, we showed that nsp14 serves as an authentic target of Bi(III)-based antivirals in SARS-CoV-2-infected mammalian cells by quantification of both the protein and inhibitor. This study highlights the importance of nsp14/nsp10 as a potential target for the development of pan-antivirals against SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
ACS infectious diseases - 10(2024), 3 vom: 08. März, Seite 858-869 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Jingxin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7LP2MPO46S |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsinfecdis.3c00356 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363894330 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363894330 | ||
| 003 | DE-627 | ||
| 005 | 20240311231933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsinfecdis.3c00356 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM363894330 | ||
| 035 | |a (NLM)37897418 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Jingxin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of Pan-Anti-SARS-CoV-2 Agents through Allosteric Inhibition of nsp14/nsp10 Complex |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SARS-CoV-2 nsp14 functions both as an exoribonuclease (ExoN) together with its critical cofactor nsp10 and as an S-adenosyl methionine-dependent (guanine-N7) methyltransferase (MTase), which makes it an attractive target for the development of pan-anti-SARS-CoV-2 drugs. Herein, we screened a panel of compounds (and drugs) and found that certain compounds, especially Bi(III)-based compounds, could allosterically inhibit both MTase and ExoN activities of nsp14 potently. We further demonstrated that Bi(III) binds to both nsp14 and nsp10, resulting in the release of Zn(II) ions from the enzymes as well as alternation of protein quaternary structures. The in vitro activities of the compounds were also validated in SARS-CoV-2-infected mammalian cells. Importantly, we showed that nsp14 serves as an authentic target of Bi(III)-based antivirals in SARS-CoV-2-infected mammalian cells by quantification of both the protein and inhibitor. This study highlights the importance of nsp14/nsp10 as a potential target for the development of pan-antivirals against SARS-CoV-2 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antiviral | |
| 650 | 4 | |a bioinorganic chemistry | |
| 650 | 4 | |a bismuth | |
| 650 | 4 | |a nsp14 Exon and MTase | |
| 650 | 7 | |a Viral Nonstructural Proteins |2 NLM | |
| 650 | 7 | |a Methyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.- |2 NLM | |
| 650 | 7 | |a S-Adenosylmethionine |2 NLM | |
| 650 | 7 | |a 7LP2MPO46S |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Zhou, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Xueying |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xiaohan |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Zhenzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, Chon Phin |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Zi-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Dong-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Boitrel, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Shuofeng |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Jasper F-W |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Hongzhe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS infectious diseases |d 2015 |g 10(2024), 3 vom: 08. März, Seite 858-869 |w (DE-627)NLM248280775 |x 2373-8227 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:3 |g day:08 |g month:03 |g pages:858-869 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsinfecdis.3c00356 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 3 |b 08 |c 03 |h 858-869 | ||